# Adaptyv Biosystems **Source:** https://geo.sig.ai/brands/adaptyv-biosystems **Vertical:** Healthcare **Subcategory:** General **Tier:** Emerging **Website:** adaptyv.bio **Last Updated:** 2026-04-14 ## Summary Lausanne Switzerland automated cloud lab for AI protein engineering at $11.2M total ($8M ACE Ventures seed 2025); improved protein success rate from 2.5% to 13% testing 10K+ proteins for 30+ pharma/biotech partners competing with Recursion for AI drug discovery. ## Company Overview Adaptyv Biosystems is a Lausanne, Switzerland-based AI-driven protein engineering platform — backed with $11.2 million in total funding including an $8 million seed round in 2025 led by ACE Ventures with participation from ByFounders, Founderful, and LongGame Ventures, following a CHF 2.5 million pre-seed in 2022 — providing pharmaceutical companies, biotechnology firms, and academic AI research groups with fully automated cloud laboratory services for validating and iterating AI-generated protein designs, enabling the experimental testing that transforms computational protein engineering from theoretical exploration to practical drug discovery. Founded in 2021 and having tested over 10,000 proteins in collaboration with 30+ pharma and biotech partners, Adaptyv has improved protein engineering success rates from the industry baseline of 2.5% to 13% — a 5x improvement that represents the breakthrough enabling practical AI-guided therapeutic protein development. Adaptyv's automated cloud laboratory eliminates the experimental bottleneck in the AI protein design cycle: AI protein design tools (AlphaFold structure prediction, RFdiffusion backbone generation, ProteinMPNN sequence design) can now generate thousands of theoretically promising protein candidates for therapeutic targets — but each candidate must be physically synthesized and experimentally tested to determine whether it actually binds its target, is stable in physiological conditions, and can be manufactured at therapeutic doses. Traditional wet lab testing (manual protein expression, purification, and characterization) creates the experimental throughput bottleneck that limits AI-guided protein engineering to testing a small fraction of computationally generated candidates. Adaptyv's automated cloud lab (robotic protein expression systems, automated biophysical characterization instruments, cloud-accessible data pipelines) processes protein candidates from DNA sequence to experimental binding and stability results in days rather than weeks, enabling AI protein design teams to run the experimental feedback loops required to optimize protein designs toward therapeutic-quality performance. In 2025, Adaptyv Biosystems competes in the protein engineering services, automated biofoundry, and AI drug discovery tools market with Twist Bioscience (NASDAQ: TWST, synthetic DNA for protein expression), Recursion Pharmaceuticals (NASDAQ: RXRX, AI drug discovery with robotic lab infrastructure), and Ginkgo Bioworks (NYSE: DNA, synthetic biology platform with automated labs) for pharma and biotech AI protein engineering experimental capacity. The AI protein engineering market has been transformed by the AlphaFold2 breakthrough (2020) and the subsequent development of protein generation tools (RFdiffusion, ProteinMPNN) that enable de novo protein design — but the experimental validation bottleneck has remained the rate-limiting step for translating computational designs into therapeutic candidates. Adaptyv's 5x success rate improvement from 2.5% to 13% demonstrates that the combination of AI-guided design and high-throughput experimental feedback creates measurably better protein candidates than computational design alone. The 2025 strategy focuses on growing the pharma partnerships for antibody and enzyme engineering programs, building the data flywheel from tested protein sequences to improve the AI design models, and expanding to protein-protein interaction engineering for the biologics immunotherapy market. ## Frequently Asked Questions ### What is Adaptyv Biosystems? Adaptyv Biosystems is a Swiss biotechnology company founded in 2021 that provides fully automated cloud laboratories for validating AI-generated proteins, creating a new paradigm for protein engineering using generative AI, open-source software, and synthetic biology. The company raised $11.2M total ### What does Adaptyv Biosystems build? Adaptyv Biosystems builds automated protein engineering platforms that use machine learning and laboratory robotics to design, produce, and test proteins at high throughput, accelerating the discovery of protein-based therapeutics and tools. ### How does Adaptyv use AI in protein engineering? Adaptyv uses AI models trained on protein sequence-function data to predict which protein variants are likely to have desired properties, guiding the selection of candidates for laboratory synthesis and testing and dramatically reducing the number of experiments needed. ### What types of proteins does Adaptyv's platform target? Adaptyv's platform is applicable across protein classes including antibodies, nanobodies, enzymes, and binding proteins, with particular focus on therapeutically relevant proteins where improved binding affinity, stability, or specificity are desired. ### Who are Adaptyv's customers? Adaptyv serves pharmaceutical and biotechnology companies that want to accelerate protein engineering campaigns, offering both platform access and contract research services to organizations looking to discover novel protein therapeutics faster. ### How does Adaptyv's platform reduce protein engineering timelines? By combining AI-guided design with automated lab workflows, Adaptyv can run dozens to hundreds of design-build-test cycles in the time it would take a traditional lab to complete a few, compressing protein optimization campaigns from years to months. ### What wet lab capabilities does Adaptyv have? Adaptyv operates automated laboratory infrastructure capable of high-throughput protein expression, purification, and functional screening, enabling the rapid empirical validation of computationally designed protein variants. ### What is the significance of the protein engineering field for drug development? Protein engineering is central to modern biopharmaceutical development. Engineered proteins form the basis of antibody therapies, bispecifics, protein degraders, and cell therapies — a significant and growing share of the drug pipeline. Faster engineering directly translates to faster drug development timelines. ## Tags healthtech, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*